Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 8/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20546589 | 0.89 | MMP12 (0.39) | CTSAATML3MBTL1FFAR1MMP3 | |
| SCHEMBL20546203 | 0.85 | CTSA (0.41) | CTSAFFAR1 | |
| SCHEMBL20545918 | 0.84 | CTSA (0.44) | CTSAFFAR1 | |
| SCHEMBL20546334 | 0.81 | FFAR1 (0.36) | CTSAATML3MBTL1FFAR1 | |
| SCHEMBL20545538 | 0.81 | CTSA (0.41) | CTSAFFAR1 | |
| SCHEMBL20546605 | 0.80 | MMP12 (0.38) | CTSAATML3MBTL1FFAR1MMP3 | |
| SCHEMBL29219665 | 0.79 | MMP12 (0.41) | L3MBTL1MMP12MMP13 | |
| SCHEMBL30671305 | 0.79 | MMP12 (0.41) | L3MBTL1MMP12MMP13 | |
| SCHEMBL30541468 | 0.79 | MMP12 (0.41) | L3MBTL1MMP12MMP13 | |
| SCHEMBL30671440 | 0.75 | MAPT (0.39) | CTSAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10875875-B2 | Propionic acid derivatives and methods of use thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20180312523-A1 | Propionic Acid Derivatives and Methods of Use Thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312523-A1 | Propionic Acid Derivatives and Methods of Use Thereof | ITGB3, ITGA1, ITGB5 | CTSA 2240/4885ATM 4354/4885L3MBTL1 3530/4885 |
| US-10875875-B2 | Propionic acid derivatives and methods of use thereof | ITGB3, ITGA1, ITGB5 | CTSA 2240/4885ATM 4354/4885L3MBTL1 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.